Goldman Sachs’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-63,090
| Closed | -$168K | – | 6055 |
|
|
2024
Q1 | $168K | Sell |
63,090
-93,136
| -60% | -$231K | ﹤0.01% | 5154 |
|
|
2023
Q4 | $370K | Buy |
156,226
+77,255
| +98% | +$137K | ﹤0.01% | 4895 |
|
|
2023
Q3 | $111K | Sell |
78,971
-80,034
| -50% | -$192K | ﹤0.01% | 5164 |
|
|
2023
Q2 | $482K | Sell |
159,005
-60,512
| -28% | -$233K | ﹤0.01% | 4772 |
|
|
2023
Q1 | $1.37M | Buy |
219,517
+147,479
| +205% | +$899K | ﹤0.01% | 4149 |
|
|
2022
Q4 | $439K | Sell |
72,038
-127,750
| -64% | -$1.04M | ﹤0.01% | 4943 |
|
|
2022
Q3 | $2.39M | Sell |
199,788
-11,170
| -5% | -$146K | ﹤0.01% | 3828 |
|
|
2022
Q2 | $2.66M | Buy |
210,958
+142,804
| +210% | +$1.33M | ﹤0.01% | 3794 |
|
|
2022
Q1 | $767K | Buy |
68,154
+11,087
| +19% | +$122K | ﹤0.01% | 5039 |
|
|
2021
Q4 | $1.01M | Sell |
57,067
-37,494
| -40% | -$791K | ﹤0.01% | 4826 |
|
|
2021
Q3 | $2.18M | Buy |
94,561
+79,349
| +522% | +$1.73M | ﹤0.01% | 4126 |
|
|
2021
Q2 | $354K | Sell |
15,212
-2,562
| -14% | -$65.2K | ﹤0.01% | 5427 |
|
|
2021
Q1 | $554K | Sell |
17,774
-42,512
| -71% | -$1.48M | ﹤0.01% | 5040 |
|
|
2020
Q4 | $2.4M | Buy |
+60,286
| New | +$2.42M | ﹤0.01% | 3597 |
|
Goldman Sachs's KNTE Position: Q2 2024 in Review
Goldman Sachs sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 63,090 shares — an estimated $168K sold.
Goldman Sachs first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $2.66M in Q2 2022. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Goldman Sachs reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Goldman Sachs sold 63,090 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $168K.
- Goldman Sachs first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
- Goldman Sachs's Kinnate Biopharma Inc. Common Stock position peaked at $2.66M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.